These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 33106917)

  • 1. Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives.
    Sun BL; Chen Y; Fan DY; Zhu C; Zeng F; Wang YJ
    Sci China Life Sci; 2021 Jun; 64(6):926-937. PubMed ID: 33106917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease.
    Bu XL; Jiao SS; Lian Y; Wang YJ
    Curr Alzheimer Res; 2016; 13(3):307-16. PubMed ID: 26667888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease.
    Pinheiro L; Faustino C
    Curr Alzheimer Res; 2019; 16(5):418-452. PubMed ID: 30907320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors.
    Kuo YC; Rajesh R
    Expert Rev Neurother; 2019 Jul; 19(7):623-652. PubMed ID: 31109210
    [No Abstract]   [Full Text] [Related]  

  • 5. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
    Behl T; Kaur I; Fratila O; Brata R; Bungau S
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
    Suzuki K; Iwata A; Iwatsubo T
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Status and future directions of clinical trials in Alzheimer's disease.
    Plascencia-Villa G; Perry G
    Int Rev Neurobiol; 2020; 154():3-50. PubMed ID: 32739008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease.
    Cho JE; Kim JR
    Recent Pat CNS Drug Discov; 2011 Sep; 6(3):222-33. PubMed ID: 21834780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying therapies in Alzheimer's disease: how far have we come?
    Hüll M; Berger M; Heneka M
    Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical to phase II amyloid beta (A
    Parsons CG; Rammes G
    Expert Opin Investig Drugs; 2017 May; 26(5):579-592. PubMed ID: 28362514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies.
    Vijayan D; Chandra R
    Curr Drug Targets; 2020; 21(2):148-166. PubMed ID: 31385768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Y
    Matrone C; Iannuzzi F; Annunziato L
    Ageing Res Rev; 2019 Jul; 52():120-128. PubMed ID: 31039414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
    Chu J; Lauretti E; Craige CP; Praticò D
    J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
    Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
    Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.
    Lin LF; Luo HM
    Neurosci Bull; 2011 Feb; 27(1):53-60. PubMed ID: 21270904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of neuroinflammation in Alzheimer's disease via nanoparticle-loaded phytocompounds with anti-inflammatory and autophagy-inducing properties.
    Nayak V; Patra S; Rout S; Jena AB; Sharma R; Pattanaik KP; Singh J; Pandey SS; Singh RP; Majhi S; Singh KR; Kerry RG
    Phytomedicine; 2024 Jan; 122():155150. PubMed ID: 37944239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of Disease-modifying Therapy for Alzheimer's Disease].
    Akiyama H
    Brain Nerve; 2016 Apr; 68(4):463-72. PubMed ID: 27056864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. gamma-Secretase as a therapeutic target in Alzheimer's disease.
    Guardia-Laguarta C; Pera M; Lleó A
    Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.